Page last updated: 2024-10-30

losartan and Pregnancy

losartan has been researched along with Pregnancy in 104 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.

Research Excerpts

ExcerptRelevanceReference
" This study determined the influence of maternal intake of high sucrose (HS) during pregnancy on vessel tone, intracellular Ca(2+) ([Ca(2+)](i)), K(+) channels, especially large-conductance Ca(2+)-activated K(+) channels (BK), in mesenteric arteries in the offspring rats exposed to prenatal HS."7.79Intake of high sucrose during pregnancy altered large-conductance Ca2+-activated K+ channels and vessel tone in offspring's mesenteric arteries. ( Cao, L; Fang, Q; Li, S; Liu, Y; Mao, C; Shi, A; Wu, L; Xu, Z; Zhou, A; Zhu, H, 2013)
"We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication."7.73In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006)
"This study was designed to investigate the effect of hyperglycemia and angiotensin II (AngII) on renal hypertrophy and proteinuria in the pregnant diabetic rat."7.72Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat. ( Boner, G; Erman, A; Gafter, U; Natif, N; Sclarovsky-Benjaminov, F; Sulkes, J; Van Dijk, DJ, 2003)
"To test this hypothesis the baroreflex relationship between arterial pressure and heart rate in conscious rabbits was determined before and after administration of the angiotensin II AT1 receptor antagonist losartan (n = 7) before pregnancy and at the end of gestation."7.71Role of angiotensin II in altered baroreflex function of conscious rabbits during late pregnancy. ( Brooks, VL; Kane, CM; Welch, LS, 2001)
"The purpose of this work was to determine which subtype of angiotensin II receptors was involved in angiotensin II-induced human placental lactogen (hPL) and pregnancy-specific beta 1-glycoprotein (SP1) secretion from human placenta."7.69Angiotensin II induces human placental lactogen and pregnancy-specific beta 1-glycoprotein secretion via an angiotensin AT1 receptor. ( de Gasparo, M; De Hertogh, R; Kalenga, MK; Thomas, K, 1994)
"Treatment with Losartan resulted in severe renal abnormalities."5.35Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. ( Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008)
" Considering that usage of angiotensin II type 1 (AT1) receptor blockers, among other renin-angiotensin system (RAS) antagonists, is associated with adverse pregnancy outcomes, here we aim to analyse the involvement of AT1 receptor in the reciprocal dialogue occurring between endometrial stroma and trophoblast cells."4.31Losartan impairs HTR-8/SVneo trophoblast migration through inhibition of angiotensin II-induced pro-inflammatory profile in human endometrial stromal cells. ( Blanco, GA; Canellada, AM; Castro, MS; Macchi, R; Parrado, AC; Rey-Roldán, EB; Salaverry, LS; Sotelo, AD, 2023)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
" Considering the role of renin-angiotensin system (RAS) in maternal programming during PE, we investigated the hypothesis that gestational modulation of offensive (Angiotensin II, Ang II) and defensive (Ang 1-7) components of RAS alleviates cardiovascular hyperresponsiveness of weaning PE mothers to postpartum endotoxemia."4.12Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic rats. ( Abuiessa, SA; El-Gowelli, HM; El-Gowilly, SM; El-Mas, MM; Helmy, MM, 2022)
" She had been taking losartan tablets before and during pregnancy."4.02Use of angiotensin II receptor blocker during pregnancy: A case report. ( Duan, MF; Huang, N; Song, CR; Wang, YM; Wei, Q; Zhang, L, 2021)
" Angiotensin II as well as phenylephrine induced vascular contraction was tested in isolated aorta rings with and without endothelium from rats fed for 7 weeks (4 before and 3 weeks during pregnancy) with standard (SD) or hypercaloric (HD) diet."3.80Experimental gestational diabetes mellitus induces blunted vasoconstriction and functional changes in the rat aorta. ( Bobadilla-Lugo, RA; Bracho-Valdés, I; Ibarra-Barajas, M; Tufiño, C; Villanueva-López, C, 2014)
" This study determined the influence of maternal intake of high sucrose (HS) during pregnancy on vessel tone, intracellular Ca(2+) ([Ca(2+)](i)), K(+) channels, especially large-conductance Ca(2+)-activated K(+) channels (BK), in mesenteric arteries in the offspring rats exposed to prenatal HS."3.79Intake of high sucrose during pregnancy altered large-conductance Ca2+-activated K+ channels and vessel tone in offspring's mesenteric arteries. ( Cao, L; Fang, Q; Li, S; Liu, Y; Mao, C; Shi, A; Wu, L; Xu, Z; Zhou, A; Zhu, H, 2013)
" Losartan abolished hypertension, suggesting that AT(1a)R plays a primary role in arterial pressure elevation."3.78Temporal alterations in vascular angiotensin receptors and vasomotor responses in offspring of protein-restricted rat dams. ( Balakrishnan, M; Chinnathambi, V; Gao, H; Sathishkumar, K; Yallampalli, C, 2012)
" We evaluated the effect of stimulation/inhibition of Ang II receptors on hindbrain development, in offspring (postnatal days P0, P8) of pregnant rats treated during late pregnancy (Ang II, Losartan or PD123319, 1 mg/kg/day)."3.75Prenatal blockade of Ang II receptors affects neonatal rat hindbrain structure and receptor localization. ( Arce, ME; Ciuffo, GM; Fuentes, LB; Sánchez, SI, 2009)
" We report a chronic hypertensive pregnant woman treated with losartan before and throughout pregnancy."3.74[Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case]. ( Catalán M, J; Hasbún H, J; Parra C, M; Salinas Q, S; San Martín O, A; Valdés R, E, 2008)
"In pregnancy there is an attenuated response to vasoconstrictors and pressor agents, including Angiotensin II (Ang II)."3.73Renal vascular responses in an experimental model of preeclampsia. ( Bobadilla Lugo, RA; López Sanchez, P; Pérez-Alvarez, VM; Robledo, LA, 2005)
"We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication."3.73In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006)
" We report a premature infant born to a 41-year-old mother with a long history of infertility who had received losartan therapy for hypertension throughout an undetected pregnancy."3.73Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant. ( Bass, JK; Faix, RG, 2006)
" The mother suffered from essential hypertension and was treated with Cozaar (losartan 50 mg)."3.73Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. ( Daïkha-Dahmane, F; Jugie, M; Lenclen, R; Levy-Beff, E, 2006)
"This study was designed to investigate the effect of hyperglycemia and angiotensin II (AngII) on renal hypertrophy and proteinuria in the pregnant diabetic rat."3.72Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat. ( Boner, G; Erman, A; Gafter, U; Natif, N; Sclarovsky-Benjaminov, F; Sulkes, J; Van Dijk, DJ, 2003)
"We report a case of maternal exposure to the antihypertensive drug losartan during weeks 20-31 of pregnancy."3.71Losartan and fetal toxic effects. ( Hagiwara, A; Ijiri, R; Saji, H; Yamanaka, M, 2001)
"To test this hypothesis the baroreflex relationship between arterial pressure and heart rate in conscious rabbits was determined before and after administration of the angiotensin II AT1 receptor antagonist losartan (n = 7) before pregnancy and at the end of gestation."3.71Role of angiotensin II in altered baroreflex function of conscious rabbits during late pregnancy. ( Brooks, VL; Kane, CM; Welch, LS, 2001)
"This study was performed to investigate the roles of angiotensin receptors (AT1 and AT2) in the contractility of uterine arteries during normal pregnancy and after angiotensin II levels have been elevated."3.70Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes. ( Burrell, JH; Gibson, KJ; Lumbers, ER; McMullen, JR; Wu, J, 1999)
"We found: (1) comparable birth weights in control and PD123319-treated animals, but reduced body weight in newborn losartan-treated animals; (2) compared to untreated animals, type I collagen and TGF-beta 1 mRNA expression in cardiac tissue were each equally reduced in both losartan and PD123319-treated animals; (3) increased type III collagen mRNA expression in both PD123319- and losartan-treated groups; and (4) a significant decrease in total soluble cardiac collagen concentration in both losartan and PD123319-treated groups, confirmed by attenuated immunoreactivity of type I and III collagens in whole heart extracts by Western blotting."3.70Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart. ( Lamparter, S; Sun, Y; Weber, KT, 1999)
"The purpose of this work was to determine which subtype of angiotensin II receptors was involved in angiotensin II-induced human placental lactogen (hPL) and pregnancy-specific beta 1-glycoprotein (SP1) secretion from human placenta."3.69Angiotensin II induces human placental lactogen and pregnancy-specific beta 1-glycoprotein secretion via an angiotensin AT1 receptor. ( de Gasparo, M; De Hertogh, R; Kalenga, MK; Thomas, K, 1994)
"Optimal cardiovascular prevention after preeclampsia should be further explored."3.11Differential effects of renin-angiotensine-aldosteron system inhibition, sympathoinhibition and low sodium diet on blood pressure in women with a history of preeclampsia: A double-blind, placebo-controlled cross-over trial (the PALM study). ( Franx, A; Groenhof, TKJ; Paauw, ND; Spiering, W; Titia Lely, A; Veerbeek, JHW; Verhaar, MC; Zoet, GA, 2022)
"In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect."2.42Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. ( Gard, PR, 2004)
"Losartan may cause hyperkalemia when used with potassium-sparing diuretics, such as spironolactone or triamterene."2.40[Drug-interactions and adverse effects of losartan potassium, an angiotensin II receptor antagonist]. ( Yoshinaga, K, 1999)
"Losartan treatment for three weeks lowered systolic blood pressure in both Control and Restricted groups but this difference was not sustained after the cessation of treatment."1.48Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health. ( Gallo, LA; Mazzuca, MQ; Moritz, KM; Parkington, HC; Tare, M; Walton, SL; Wlodek, ME, 2018)
"Losartan decreased cardiac hypertrophy and fibrosis and improved left ventricle fraction of shortening in P28 O2-exposed rats, which was associated with decreased oxidation of calcium/calmodulin-dependent protein kinase II, inhibition of the transforming growth factor-β/SMAD3 pathway, and upregulation of cardiac angiotensin-converting enzyme 2."1.43Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. ( Béland-Bonenfant, S; Bertagnolli, M; Cloutier, A; Dios, A; Gascon, G; Lukaszewski, MA; Nuyt, AM; Paradis, P; Schiffrin, EL; Sutherland, M, 2016)
"Co-treatment with losartan significantly attenuated the release of sEng and sEng mRNA expression in the trophoblast cells."1.42Autoantibodies isolated from patients with preeclampsia induce soluble endoglin production from trophoblast cells via interactions with angiotensin II type 1 receptor. ( Chishima, F; Kobayashi, Y; Suzuki, M; Takahashi, H; Yamamoto, T, 2015)
"Treatment with losartan during the course of testosterone exposure significantly attenuated testosterone-induced hypertension."1.40Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats. ( Chinnathambi, V; Hankins, GD; More, AS; Sathishkumar, K; Yallampalli, C, 2014)
"Normal pregnancy is associated with reduced blood pressure (BP) and decreased pressor response to vasoconstrictors, even though the renin-angiotensin system is upregulated."1.35Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats. ( Falone, AE; Khalil, RA; Koledova, VV; Qiao, X; Stennett, AK, 2009)
"Preeclampsia is a serious pathologic complication during pregnancy, and its pathogenesis remains poorly understood."1.35Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. ( Chang, H; Cheng, X; Liu, H; Ma, XL; Wang, F; Wang, X; Yang, L; Yang, X; Zhang, M; Zhang, S, 2008)
"Nicotine was administered to pregnant rats via subcutaneous osmotic minipumps throughout the gestation."1.35Prenatal gender-related nicotine exposure increases blood pressure response to angiotensin II in adult offspring. ( Huang, X; Longo, LD; Xiao, D; Xu, Z; Yang, S; Zhang, L, 2008)
"Treatment with Losartan resulted in severe renal abnormalities."1.35Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney. ( Ciuffo, GM; Forneris, ML; Fuentes, LB; Sánchez, SI; Seltzer, AM, 2008)
"The losartan-treated group also showed significantly increased mean tubular diameter and interstitial area of the kidney (P<0."1.33AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney. ( Bae, IS; Choi, BM; Hong, YS; Kim, JH; Kim, MK; Lee, JW; Yim, HE; Yoo, KH, 2006)
"Losartan is a specific angiotensin II receptor antagonist."1.32Losartan induced fetal toxicity. ( Aggarwal, R; Malhotra, N; Nayar, B; Singhal, A, 2003)
"Losartan alone treated animals had no postnatal increase in either MABP or RSNA, responses similar to those seen in nontreated sheep delivered at the same gestational age."1.31Glucocorticoid modulation of cardiovascular and autonomic function in preterm lambs: role of ANG II. ( Bedell, KA; Segar, JL; Smith, OJ, 2001)
"Body weights were 10% lower in the LO group at the start but remained unchanged relative to the CO group during the entire 8-day period of observation."1.31AT(1) receptor blockade with losartan during gestation in Wistar rats leads to an increase in thirst and sodium appetite in their adult female offspring. ( Butler, DG; Midgely, A; Nemati, B; Pak, SH, 2002)
"Preeclampsia is characterized by an increase in vascular tone associated with reduced uteroplacental flow."1.30The role of AT1 angiotensin receptor activation in the pathogenesis of preeclampsia. ( Doering, TP; Freeman, EJ; Haller, NA; Hopkins, MP; Montgomery, MA, 1998)
" There were no adverse effects on the F1 generation as assessed by mortality, clinical signs, weight gain, external examinations, developmental signs, behavioral tests, and gross or microscopic examination of the kidney."1.29Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. ( Allen, HL; Cukierski, MA; Eydelloth, RS; Manson, JM; Robertson, RT; Spence, SG, 1995)
" Following daily oral dosing of 135 mg/kg/day on GD6-15, fetal drug levels were negligible."1.29Toxicokinetic analysis of losartan during gestation and lactation in the rat. ( Baldwin, CL; Berna, RA; Eydelloth, RS; Lee, LL; Mattson, BA; Spence, SG; Zacchei, AG, 1996)

Research

Studies (104)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's19 (18.27)18.2507
2000's48 (46.15)29.6817
2010's29 (27.88)24.3611
2020's8 (7.69)2.80

Authors

AuthorsStudies
Zoet, GA1
Paauw, ND1
Veerbeek, JHW1
Groenhof, TKJ1
Spiering, W1
Verhaar, MC1
Franx, A1
Titia Lely, A1
Abuiessa, SA1
Helmy, MM1
El-Gowelli, HM1
El-Gowilly, SM1
El-Mas, MM1
Macchi, R1
Sotelo, AD1
Parrado, AC1
Salaverry, LS1
Blanco, GA1
Castro, MS1
Rey-Roldán, EB1
Canellada, AM1
Bo, L1
Wei, L1
Shi, L4
Luo, C1
Gao, S1
Zhou, A2
Mao, C5
Zhang, M2
Lu, L1
Zhang, Y7
Li, X5
Fan, X1
Chen, X3
Tang, J2
Han, B1
Li, M1
Tao, J2
Gao, Q3
Xu, Z8
Sun, M2
Warrington, JP1
Fan, F1
Duncan, J1
Cunningham, MW2
LaMarca, BB2
Dechend, R5
Wallukat, G5
Roman, RJ1
Drummond, HA1
Granger, JP3
Ryan, MJ1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J2
Zhang, J1
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J7
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J1
Wang, Y3
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, Y4
Wei, J1
Zhu, C1
Wu, C2
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y3
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Wang, L3
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H1
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Guo, X1
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H3
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X2
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Huang, Y1
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Li, P1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Wang, X2
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y3
Zhang, Q1
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H3
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S3
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Zhou, W1
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H3
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W2
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y1
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L2
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Zhang, X1
Qian, H1
Yang, X3
Sun, Y2
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Yang, W1
Barros, MAV1
de Brito Alves, JL1
Barros, RGN1
Santana E Silva, M1
Nasser, S1
Tourneur, Y1
Leandro, CVG1
Vidal, H1
Pirola, L1
Costa-Silva, JH1
Wei, Q1
Zhang, L3
Duan, MF1
Wang, YM1
Huang, N1
Song, CR1
Yu, T1
Qu, M1
Dong, F1
Wang, F3
Zhang, F1
Zhou, X1
Man, D1
de Queiroz, DB1
Ramos-Alves, FE1
Santos-Rocha, J1
Duarte, GP1
Xavier, FE1
Walton, SL1
Mazzuca, MQ1
Tare, M1
Parkington, HC1
Wlodek, ME1
Moritz, KM3
Gallo, LA1
Cavalim Vale, AP1
Dos Santos, G1
da Silva, TP1
Mansano, NDS1
Chies, AB1
Chagas, EFB1
Spadella, MA1
Tao, H1
Rui, C1
Zheng, J1
Wu, L2
Shi, A2
Chen, N1
He, R1
Yin, X1
Zhang, P1
Zhu, Z1
Xiao, J1
West, CA1
Shaw, S1
Sasser, JM1
Fekete, A1
Alexander, T1
Masilamani, SM1
Baylis, C1
Lau, WB1
Zhang, S3
Ma, XL2
van der Graaf, AM1
Wiegman, MJ1
Plösch, T1
Zeeman, GG1
van Buiten, A1
Henning, RH1
Buikema, H1
Faas, MM1
Norris, AW1
Bahr, TM1
Scholz, TD2
Peterson, ES1
Volk, KA1
Segar, JL3
Chinnathambi, V2
More, AS1
Hankins, GD1
Yallampalli, C2
Sathishkumar, K2
Wang, HP1
Zhang, WH1
Wang, XF1
Zhu, J1
Zheng, YQ1
Xia, Q1
Zhi, JM1
Kobayashi, Y1
Yamamoto, T1
Chishima, F1
Takahashi, H1
Suzuki, M1
Tufiño, C1
Villanueva-López, C1
Ibarra-Barajas, M1
Bracho-Valdés, I1
Bobadilla-Lugo, RA1
Lengellé, C1
Bejan-Angoulvant, T1
Beau-Salinas, F1
Jonville-Béra, AP1
Bertagnolli, M1
Dios, A1
Béland-Bonenfant, S1
Gascon, G1
Sutherland, M1
Lukaszewski, MA1
Cloutier, A1
Paradis, P1
Schiffrin, EL1
Nuyt, AM1
Gowrisankar, YV1
Clark, MA1
Chang, H1
Yang, L1
Cheng, X1
Hasbún H, J1
Valdés R, E1
San Martín O, A1
Catalán M, J1
Salinas Q, S1
Parra C, M1
LaMarca, B3
Llinas, M1
Herse, F3
Stennett, AK1
Qiao, X1
Falone, AE1
Koledova, VV1
Khalil, RA1
Gersak, K1
Cvijic, M1
Cerar, LK1
Anton, L1
Merrill, DC1
Neves, LA1
Diz, DI2
Corthorn, J1
Valdes, G1
Stovall, K1
Gallagher, PE2
Moorefield, C1
Gruver, C1
Brosnihan, KB1
Sánchez, SI2
Arce, ME1
Fuentes, LB2
Ciuffo, GM3
Cui, XL1
Chang, B1
Myatt, L1
Irani, RA1
Blackwell, SC1
Zhou, CC1
Ramin, SM1
Kellems, RE1
Xia, Y1
Gwathmey, TM1
Shaltout, HA1
Rose, JC1
Chappell, MC2
Singh, RR1
Wintour, EM2
Jefferies, AJ2
Iqbal, J1
Bertram, JF1
Denton, KM1
Esposito, F1
Galfetti, M1
Lava, SA1
Balestra, B1
Bianchetti, MG1
Marin, EC1
Francescato, HD1
da Silva, CG1
Costa, RS1
Coimbra, TM1
Moltzer, E1
te Riet, L1
Swagemakers, SM1
van Heijningen, PM1
Vermeij, M1
van Veghel, R1
Bouhuizen, AM1
van Esch, JH1
Lankhorst, S1
Ramnath, NW1
de Waard, MC1
Duncker, DJ1
van der Spek, PJ1
Rouwet, EV1
Danser, AH1
Essers, J1
Chou, HC1
Lang, YD1
Wang, LF1
Wu, TY1
Hsieh, YF1
Chen, CM1
Saito, T1
Musha, Y1
Miyakawa, M1
Itoh, S1
Ohtsuji, M1
Hanson, MA1
Takeda, S1
Novotny, SR1
Wallace, K2
Heath, J2
Moseley, J1
Dhillon, P1
Weimer, A1
Wenzel, K1
Martin, JN2
Balakrishnan, M1
Gao, H1
Dhillion, P1
Scott, J1
Mosely, J1
Li, S1
Fang, Q1
Cao, L1
Resch, BE1
Gaspar, R1
Sonkodi, S1
Falkay, G1
Natif, N1
Sclarovsky-Benjaminov, F1
Van Dijk, DJ1
Sulkes, J1
Gafter, U1
Boner, G1
Erman, A1
Nayar, B1
Singhal, A1
Aggarwal, R1
Malhotra, N1
Swenson, SJ1
Speth, RC1
Porter, JP1
Racasan, S1
Hahnel, B1
van der Giezen, DM1
Blezer, EL1
Goldschmeding, R1
Braam, B1
Kriz, W1
Koomans, HA1
Joles, JA1
Gard, PR1
Donadio, MV1
Sagae, SC1
Franci, CR1
Anselmo-Franci, JA1
Lucion, AB1
Sanvitto, GL1
Yao, J2
Koos, BJ1
El-Haddad, MA1
Ismail, Y1
Gayle, D1
Ross, MG1
Cruden, NL1
Tse, GH1
Fox, KA1
Ludlam, CA1
Megson, I1
Newby, DE1
Ferrario, CM1
Tallant, EA1
Akil, I1
Inan, S1
Gurcu, B1
Nazikoglu, A1
Ozbilgin, K1
Muftuoglu, S1
Thornton, SN1
Wu, J3
Roberts, L1
Fournier, L1
Bain, J1
Cockrell, K1
Bobadilla Lugo, RA1
Pérez-Alvarez, VM1
Robledo, LA1
López Sanchez, P1
Dodic, M1
McAlinden, AT1
Cock, ML1
May, CN1
Evans, RG1
St-Louis, J3
Sicotte, B2
Beauséjour, A1
Brochu, M3
Daïkha-Dahmane, F2
Levy-Beff, E1
Jugie, M1
Lenclen, R1
Habashi, JP1
Judge, DP1
Holm, TM1
Cohn, RD1
Loeys, BL1
Cooper, TK1
Myers, L1
Klein, EC1
Liu, G1
Calvi, C1
Podowski, M1
Neptune, ER1
Halushka, MK1
Bedja, D1
Gabrielson, K1
Rifkin, DB1
Carta, L1
Ramirez, F1
Huso, DL1
Dietz, HC1
Morrissey, P1
Lee, J1
Bass, JK1
Faix, RG1
Yim, HE1
Kim, MK1
Bae, IS1
Kim, JH1
Choi, BM1
Yoo, KH1
Hong, YS1
Lee, JW1
Bakkum, JN1
Brost, BC1
Johansen, KL1
Johnston, BW1
Watson, WJ1
Ceravolo, GS1
Franco, MC1
Carneiro-Ramos, MS1
Barreto-Chaves, ML1
Tostes, RC1
Nigro, D1
Fortes, ZB1
Carvalho, MH1
Miyoshi, M1
Miyano, K1
Moriyama, N1
Taniguchi, M1
Watanabe, T1
Xiao, D1
Huang, X1
Longo, LD1
Roghair, RD1
Miller, FJ1
Lamb, FS1
Machado, FG1
Poppi, EP1
Fanelli, C1
Malheiros, DM1
Zatz, R1
Fujihara, CK1
Seltzer, AM1
Forneris, ML1
McCoy, R1
Spence, SG3
Allen, HL1
Cukierski, MA2
Manson, JM2
Robertson, RT2
Eydelloth, RS3
Kalenga, MK1
de Gasparo, M1
Thomas, K1
De Hertogh, R1
Forcier, I1
Saridogan, E1
Djahanbakhch, O1
Puddefoot, JR1
Demetroulis, C1
Collingwood, K1
Mehta, JG1
Vinson, GP1
Bing, C1
Johnson, IR1
Broughton Pipkin, F1
Moeller, I1
Chai, SY1
MacGregor, DP1
Aldred, GP1
Mendelsohn, FA1
Bastien, NR1
Saavedra, JM2
Lambert, C1
Stevenson, KM1
Gibson, KJ3
Lumbers, ER3
Zacchei, AG1
Lee, LL1
Baldwin, CL1
Berna, RA1
Mattson, BA1
Breault, L1
Lehoux, JG1
Gallo-Payet, N1
Doering, TP1
Haller, NA1
Montgomery, MA1
Freeman, EJ1
Hopkins, MP1
Zwart, AS1
Davis, EA1
Widdop, RE1
Yoshinaga, K1
Mann, R1
Mackay, F1
Pearce, G1
Freemantle, S1
Wilton, L1
McMullen, JR2
Burrell, JH2
Lamparter, S1
Weber, KT1
Sherman, RC1
Langley-Evans, SC1
Homuth, V1
Kreuzer, J1
Park, JK1
Theuer, J1
Juepner, A1
Gulba, DC1
Mackman, N1
Haller, H1
Luft, FC1
Bedell, KA1
Smith, OJ1
Saji, H1
Yamanaka, M1
Hagiwara, A1
Ijiri, R1
Brooks, VL1
Welch, LS1
Kane, CM1
O'Hagan, KP1
Skogg, KA1
Stevenson, JB1
Lambot, MA1
Vermeylen, D1
Noël, JC1
Martinovic, J1
Benachi, A1
Laurent, N1
Gubler, MC1
Bédard, S1
Butler, DG1
Pak, SH1
Midgely, A1
Nemati, B1
Tsutsumi, K1
Viswanathan, M1
Strömberg, C1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124]Phase 3291 participants (Anticipated)Interventional2008-07-31Recruiting
No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately[NCT05090449]Phase 136 participants (Actual)Interventional2019-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for losartan and Pregnancy

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
    Expert opinion on therapeutic targets, 2004, Volume: 8, Issue:1

    Topics: Aging; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2004
[Drug-interactions and adverse effects of losartan potassium, an angiotensin II receptor antagonist].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:5

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Drug Interactions; Female; Humans; Losart

1999

Trials

3 trials available for losartan and Pregnancy

ArticleYear
Differential effects of renin-angiotensine-aldosteron system inhibition, sympathoinhibition and low sodium diet on blood pressure in women with a history of preeclampsia: A double-blind, placebo-controlled cross-over trial (the PALM study).
    Pregnancy hypertension, 2022, Volume: 27

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Cross-Over

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:4

    Topics: Adolescent; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin B1 R

2005

Other Studies

99 other studies available for losartan and Pregnancy

ArticleYear
Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic rats.
    European journal of pharmacology, 2022, Dec-05, Volume: 936

    Topics: Angiotensin II; Animals; Endotoxemia; Female; Humans; Losartan; Peptidyl-Dipeptidase A; Pioglitazone

2022
Losartan impairs HTR-8/SVneo trophoblast migration through inhibition of angiotensin II-induced pro-inflammatory profile in human endometrial stromal cells.
    Toxicology and applied pharmacology, 2023, 02-15, Volume: 461

    Topics: Angiotensin II; Endometrium; Female; Humans; Losartan; Matrix Metalloproteinase 2; Pregnancy; Prolac

2023
Altered local RAS in the liver increased the risk of NAFLD in male mouse offspring produced by in vitro fertilization.
    BMC pregnancy and childbirth, 2023, May-12, Volume: 23, Issue:1

    Topics: Animals; Diet, High-Fat; Female; Fertilization in Vitro; Glucose; Humans; Lipids; Liver; Losartan; M

2023
Methylation-reprogrammed AGTR1 results in increased vasoconstriction by angiotensin II in human umbilical cord vessel following in vitro fertilization-embryo transfer.
    Life sciences, 2019, Oct-01, Volume: 234

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An

2019
The angiotensin II type I receptor contributes to impaired cerebral blood flow autoregulation caused by placental ischemia in pregnant rats.
    Biology of sex differences, 2019, 12-11, Volume: 10, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cerebrovascular Circulation; Female; Homeostasis;

2019
Effects of maternal protein restriction on central and peripheral renin-angiotensin systems in male rat offspring.
    Life sciences, 2020, Dec-15, Volume: 263

    Topics: Animals; Arterial Pressure; Diet, Protein-Restricted; Female; Heart Rate; Hypertension; Lactation; L

2020
Use of angiotensin II receptor blocker during pregnancy: A case report.
    Medicine, 2021, Jan-22, Volume: 100, Issue:3

    Topics: Adult; Angiotensin Receptor Antagonists; Female; Humans; Losartan; Nephrotic Syndrome; Oligohydramni

2021
Prenatal High-Sucrose Diet Induced Vascular Dysfunction in Thoracic Artery of Fetal Offspring.
    Molecular nutrition & food research, 2021, Volume: 65, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Dietary Sucrose; Endothelium, Vascula

2021
Losartan reverses COX-2-dependent vascular dysfunction in offspring of hyperglycaemic rats.
    Life sciences, 2017, Sep-01, Volume: 184

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 2; Endothelium, Vas

2017
Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health.
    Pharmacological research, 2018, Volume: 134

    Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Birth Weight; Blood

2018
Influence of the AT1 Receptor Antagonists Telmisartan and Losartan on Reproduction and Offspring After Paternal Exposure to Ionizing Radiation.
    Reproductive sciences (Thousand Oaks, Calif.), 2019, Volume: 26, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fetal Viability; Losartan; Male; Paternal

2019
Angiotensin II-mediated vascular changes in aged offspring rats exposed to perinatal nicotine.
    Peptides, 2013, Volume: 44

    Topics: Acetylcholine; Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdom

2013
Chronic vasodilation increases renal medullary PDE5A and α-ENaC through independent renin-angiotensin-aldosterone system pathways.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2013, Nov-15, Volume: 305, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr

2013
Autoantibodies isolated from preeclamptic patients induce endothelial dysfunction via interaction with the angiotensin II AT1 receptor.
    Cardiovascular toxicology, 2014, Volume: 14, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Caspases; Cells, Cultured; Dose-Re

2014
Endothelium-dependent relaxation and angiotensin II sensitivity in experimental preeclampsia.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Cyclooxygenase 1; Cyclooxyg

2013
Angiotensin II-induced cardiovascular load regulates cardiac remodeling and related gene expression in late-gestation fetal sheep.
    Pediatric research, 2014, Volume: 75, Issue:6

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascul

2014
Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats.
    Biology of reproduction, 2014, Volume: 91, Issue:1

    Topics: Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Female; Hypertension, Pregnancy-Ind

2014
Exposure to AT1 receptor autoantibodies during pregnancy increases susceptibility of the maternal heart to postpartum ischemia-reperfusion injury in rats.
    International journal of molecular sciences, 2014, Jun-27, Volume: 15, Issue:7

    Topics: Animals; Autoantibodies; Collagen; Female; Heart Ventricles; Losartan; Mitochondria, Heart; Pre-Ecla

2014
Autoantibodies isolated from patients with preeclampsia induce soluble endoglin production from trophoblast cells via interactions with angiotensin II type 1 receptor.
    American journal of reproductive immunology (New York, N.Y. : 1989), 2015, Volume: 73, Issue:4

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antigens, CD; Autoantibodies; Case-Control Studies;

2015
Experimental gestational diabetes mellitus induces blunted vasoconstriction and functional changes in the rat aorta.
    BioMed research international, 2014, Volume: 2014

    Topics: Angiotensin II; Animals; Diabetes Mellitus, Experimental; Diabetes, Gestational; Female; Humans; Los

2014
[Drugs news].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2015, Volume: 22, Issue:11

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Anticonvu

2015
Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction.
    Hypertension (Dallas, Tex. : 1979), 2016, Volume: 67, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cardiomegaly; Disease Models, An

2016
Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures.
    Journal of neurochemistry, 2016, Volume: 138, Issue:1

    Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Astrocytes; Brain; Cells, Cultured; Dose-Response R

2016
Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation.
    Journal of hypertension, 2008, Volume: 26, Issue:8

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Autoantibodies; Dose-Respo

2008
[Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case].
    Revista medica de Chile, 2008, Volume: 136, Issue:5

    Topics: Acute Kidney Injury; Adult; Angiotensin II Type 1 Receptor Blockers; Creatinine; Female; Gestational

2008
Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Blood Pressure; Female; Hypertensi

2008
Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 296, Issue:3

    Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressu

2009
Angiotensin II receptor blockers in pregnancy: a report of five cases.
    Reproductive toxicology (Elmsford, N.Y.), 2009, Volume: 28, Issue:1

    Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe

2009
The uterine placental bed Renin-Angiotensin system in normal and preeclamptic pregnancy.
    Endocrinology, 2009, Volume: 150, Issue:9

    Topics: Alanine; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Down-Regulation; Female; Ge

2009
Prenatal blockade of Ang II receptors affects neonatal rat hindbrain structure and receptor localization.
    Experimental neurology, 2009, Volume: 220, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Autoradiography; Female; Fetus;

2009
Expression and distribution of NADPH oxidase isoforms in human myometrium--role in angiotensin II-induced hypertrophy.
    Biology of reproduction, 2010, Volume: 82, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cell Line; Female; Gene Expression; Humans;

2010
The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia.
    The Journal of experimental medicine, 2009, Nov-23, Volume: 206, Issue:12

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Autoantibodies; CHO Cells; Crice

2009
Glucocorticoid-induced fetal programming alters the functional complement of angiotensin receptor subtypes within the kidney.
    Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:3

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Betamethason

2011
Fetal uninephrectomy in male sheep alters the systemic and renal responses to angiotensin II infusion and AT1R blockade.
    American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Female; Heart Rate

2011
Fetopathy probably associated to self-medication with a blocker of the renin-angiotensin system.
    Archives of gynecology and obstetrics, 2011, Volume: 284, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antimalarials; Cesarean

2011
Postnatal renal abnormalities in rats exposed to losartan during lactation.
    Nephron. Experimental nephrology, 2011, Volume: 119, Issue:3

    Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Apoptosis; Creatinine; D

2011
Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade.
    PloS one, 2011, Volume: 6, Issue:8

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aorta, Thoracic;

2011
Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 340, Issue:1

    Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Blotting, Western; Body

2012
Angiotensin II receptor antagonist reduces subsequent uterine arterial dysfunction in pregnant offspring of protein-restricted rat dams.
    The journal of obstetrics and gynaecology research, 2012, Volume: 38, Issue:3

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II Type 1 Receptor B

2012
Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2012, May-15, Volume: 302, Issue:10

    Topics: Adoptive Transfer; Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Blood Pressure;

2012
Temporal alterations in vascular angiotensin receptors and vasomotor responses in offspring of protein-restricted rat dams.
    American journal of obstetrics and gynecology, 2012, Volume: 206, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Pressure; Diet, Protein-Restrict

2012
IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2012, Aug-15, Volume: 303, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Monoclonal, Murine-Derived; Antioxidan

2012
Intake of high sucrose during pregnancy altered large-conductance Ca2+-activated K+ channels and vessel tone in offspring's mesenteric arteries.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Angiotensin II; Animals; Animals, Newborn; Dietary Carbohydrates; Dose-Response Relationship, Drug;

2013
Vasoactive effects of erythropoietin on human placental blood vessels in vitro.
    American journal of obstetrics and gynecology, 2003, Volume: 188, Issue:4

    Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteries; Captopr

2003
Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat.
    The Journal of laboratory and clinical medicine, 2003, Volume: 142, Issue:3

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Drug Therapy, Com

2003
Losartan induced fetal toxicity.
    Indian journal of pediatrics, 2003, Volume: 70, Issue:11

    Topics: Abnormalities, Drug-Induced; Antihypertensive Agents; Female; Fetal Death; Heart Defects, Congenital

2003
Effect of a perinatal high-salt diet on blood pressure control mechanisms in young Sprague-Dawley rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2004, Volume: 286, Issue:4

    Topics: Adrenergic alpha-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Ani

2004
Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension.
    Kidney international, 2004, Volume: 65, Issue:2

    Topics: Animals; Animals, Suckling; Antihypertensive Agents; Blood Pressure; Captopril; Female; Hypertension

2004
Angiotensin II receptors in the arcuate nucleus mediate stress-induced reduction of prolactin secretion in steroid-primed ovariectomized and lactating rats.
    Brain research, 2004, Apr-23, Volume: 1006, Issue:1

    Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Arcuate Nucleus of Hypothalamus; Fe

2004
Induced fetal depressor or pressor responses associated with c-fos by intravenous or intracerebroventricular losartan.
    Brain research. Developmental brain research, 2004, Oct-15, Volume: 153, Issue:1

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain; Cardiovascu

2004
Central angiotensin II AT1 receptors mediate fetal swallowing and pressor responses in the near-term ovine fetus.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 288, Issue:4

    Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Blood Gas Analysis; Blood Pressure; Brain Chemistry

2005
Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes.
    American journal of physiology. Cell physiology, 2006, Volume: 290, Issue:2

    Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym

2006
Histopathological and ultrastructural effects of Losartan on embryonic rat kidney.
    Acta histochemica, 2005, Volume: 107, Issue:4

    Topics: Animals; Apoptosis; Disease Models, Animal; Epithelial Cells; Female; Glomerular Basement Membrane;

2005
Effects of intracerebroventricular losartan on angiotensin II-mediated pressor responses and c-fos expression in near-term ovine fetus.
    The Journal of comparative neurology, 2005, Dec-26, Volume: 493, Issue:4

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressu

2005
Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Endothelial Cells; Endothelins; F

2006
Renal vascular responses in an experimental model of preeclampsia.
    Proceedings of the Western Pharmacology Society, 2005, Volume: 48

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Coarctation; Blood Pressure

2005
Differential effects of prenatal exposure to dexamethasone or cortisol on circulatory control mechanisms mediated by angiotensin II in the central nervous system of adult sheep.
    The Journal of physiology, 2006, Mar-15, Volume: 571, Issue:Pt 3

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pr

2006
Remodeling and angiotensin II responses of the uterine arcuate arteries of pregnant rats are altered by low- and high-sodium intake.
    Reproduction (Cambridge, England), 2006, Volume: 131, Issue:2

    Topics: Aldosterone; Angiotensin II; Animals; Arteries; Dose-Response Relationship, Drug; Female; Losartan;

2006
Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists.
    Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:5

    Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Diseases in Twins; Fema

2006
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
    Science (New York, N.Y.), 2006, Apr-07, Volume: 312, Issue:5770

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta; Ao

2006
Effects of i.c.v. losartan on the angiotensin II-mediated vasopressin release and hypothalamic fos expression in near-term ovine fetuses.
    Peptides, 2006, Volume: 27, Issue:9

    Topics: Angiotensin II; Animals; Arginine Vasopressin; Female; Fetus; Hypothalamus; Imidazoles; Injections,

2006
Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
    American journal of perinatology, 2006, Volume: 23, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Inf

2006
AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney.
    Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:10

    Topics: Actins; Activin Receptors, Type I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angioten

2006
In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis.
    Obstetrics and gynecology, 2006, Volume: 108, Issue:3 Pt 2

    Topics: Angiotensin II Type 1 Receptor Blockers; Contraindications; Diabetes Mellitus, Type 2; Female; Fetal

2006
Enalapril and losartan restored blood pressure and vascular reactivity in intrauterine undernourished rats.
    Life sciences, 2007, Jan-30, Volume: 80, Issue:8

    Topics: Animals; Antihypertensive Agents; Arterioles; Blood Glucose; Blood Pressure; Drug Antagonism; Enalap

2007
Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor kappaB and activator protein-1 activation.
    The European journal of neuroscience, 2008, Volume: 27, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Female; Lipopolysaccharides; Losa

2008
Prenatal gender-related nicotine exposure increases blood pressure response to angiotensin II in adult offspring.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:4

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; Calcium; Enzym

2008
Coronary constriction to angiotensin II is enhanced by endothelial superoxide production in sheep programmed by dexamethasone.
    Pediatric research, 2008, Volume: 63, Issue:4

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An

2008
AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury.
    American journal of physiology. Renal physiology, 2008, Volume: 294, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Female; Hypertension, Rena

2008
Inhibition of Angiotensin II receptors during pregnancy induces malformations in developing rat kidney.
    European journal of pharmacology, 2008, Jun-24, Volume: 588, Issue:1

    Topics: Abnormalities, Drug-Induced; Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiote

2008
A new class of antihypertensive: angiotensin II receptor antagonists.
    South Dakota journal of medicine, 1995, Volume: 48, Issue:9

    Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Dose-Response

1995
Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats.
    Teratology, 1995, Volume: 51, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Antihypertensive Agents; Arterioles; Bi

1995
Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats.
    Teratology, 1995, Volume: 51, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Body Weight;

1995
Angiotensin II induces human placental lactogen and pregnancy-specific beta 1-glycoprotein secretion via an angiotensin AT1 receptor.
    European journal of pharmacology, 1994, Jul-15, Volume: 268, Issue:2

    Topics: Angiotensin II; Biphenyl Compounds; Female; Humans; Imidazoles; Losartan; Oligopeptides; Placenta; P

1994
Angiotensin II receptor subtypes in the adrenals of pregnant rats.
    Molecular and cellular endocrinology, 1995, Oct-30, Volume: 114, Issue:1-2

    Topics: Adrenal Glands; Adrenal Medulla; Angiotensin II; Animals; Binding, Competitive; Biphenyl Compounds;

1995
Angiotensin II receptors and angiotensin II stimulation of ciliary activity in human fallopian tube.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:7

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cilia; Fallopian Tubes; Female

1996
Angiotensin receptors in myometrium and myometrial vessels from uteri of women during the follicular and luteal phases of the menstrual cycle and in late pregnancy.
    Clinical science (London, England : 1979), 1996, Volume: 90, Issue:6

    Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Vessels; Cell Mem

1996
Localization and quantitation of angiotensin AT1 and AT2 receptors in the pregnant and non-pregnant sheep uterus.
    Regulatory peptides, 1996, Mar-22, Volume: 61, Issue:3

    Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Anestrus; Angiotensin II; Angiotensin Receptor Antagonists;

1996
Angiotensin II receptor expression in the conduction system and arterial duct of neonatal and adult rat hearts.
    Regulatory peptides, 1996, May-07, Volume: 63, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Atrioventricular Node;

1996
Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep.
    Clinical and experimental pharmacology & physiology, 1996, Volume: 23, Issue:2

    Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Fluids; Female; Fetus; Im

1996
Toxicokinetic analysis of losartan during gestation and lactation in the rat.
    Teratology, 1996, Volume: 53, Issue:4

    Topics: Animals; Antihypertensive Agents; Area Under Curve; Biphenyl Compounds; Female; Imidazoles; Lactatio

1996
The angiotensin AT2 receptor is present in the human fetal adrenal gland throughout the second trimester of gestation.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:11

    Topics: Adrenal Glands; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Autoradiography; Binding, C

1996
The role of AT1 angiotensin receptor activation in the pathogenesis of preeclampsia.
    American journal of obstetrics and gynecology, 1998, Volume: 178, Issue:6

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Endotoxins; Female; Fetus; L

1998
Modulation of AT1 receptor-mediated contraction of rat uterine artery by AT2 receptors.
    British journal of pharmacology, 1998, Volume: 125, Issue:7

    Topics: Angiotensin II; Animals; Arteries; Female; Imidazoles; Losartan; Oligopeptides; Phenylephrine; Pregn

1998
Losartan: a study of pharmacovigilance data on 14,522 patients.
    Journal of human hypertension, 1999, Volume: 13, Issue:8

    Topics: Age Distribution; Aged; Antihypertensive Agents; Cohort Studies; Cough; Dizziness; Female; Humans; I

1999
Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes.
    European journal of pharmacology, 1999, Aug-06, Volume: 378, Issue:2

    Topics: Angiotensin I; Angiotensin II; Animals; Anti-Arrhythmia Agents; Arteries; Female; Hypersensitivity;

1999
Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart.
    Cardiovascular research, 1999, Volume: 43, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Birth Weight; Blotting, Western; Collagen

1999
Antihypertensive treatment in early postnatal life modulates prenatal dietary influences upon blood pressure in the rat.
    Clinical science (London, England : 1979), 2000, Volume: 98, Issue:3

    Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animal Nutritional Physiological Phenomena;

2000
AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor.
    Circulation, 2000, May-23, Volume: 101, Issue:20

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies; Cells, Cultured; CHO Cells; C

2000
Glucocorticoid modulation of cardiovascular and autonomic function in preterm lambs: role of ANG II.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2001, Volume: 280, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Autonomic Nervous Syste

2001
Losartan and fetal toxic effects.
    Lancet (London, England), 2001, Feb-03, Volume: 357, Issue:9253

    Topics: Adult; Antihypertensive Agents; Contraindications; Female; Fetal Death; Humans; Losartan; Oligohydra

2001
Role of angiotensin II in altered baroreflex function of conscious rabbits during late pregnancy.
    American journal of obstetrics and gynecology, 2001, Volume: 184, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Bloo

2001
AT1 receptor block does not affect arterial baroreflex during pregnancy in rabbits.
    American journal of physiology. Heart and circulatory physiology, 2001, Volume: 280, Issue:5

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Barorefle

2001
Angiotensin-II-receptor inhibitors in pregnancy.
    Lancet (London, England), 2001, May-19, Volume: 357, Issue:9268

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Antihypertensive Agents; Cesarean Secti

2001
Fetal toxic effects and angiotensin-II-receptor antagonists.
    Lancet (London, England), 2001, Jul-21, Volume: 358, Issue:9277

    Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensi

2001
Blockade of angiotensin receptor subtypes in arcuate uterine artery of pregnant and postpartum rats.
    Hypertension (Dallas, Tex. : 1979), 2001, Volume: 38, Issue:5

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arteries; Culture Techniques; Dose-Respon

2001
AT(1) receptor blockade with losartan during gestation in Wistar rats leads to an increase in thirst and sodium appetite in their adult female offspring.
    Regulatory peptides, 2002, Apr-15, Volume: 105, Issue:1

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Appetite; Blood Pressure; Body Weight; Carotid Art

2002
125I[Sar(1)Ile(8)] angiotensin II has a different affinity for AT(1) and AT(2) receptor subtypes in ovine tissues.
    Regulatory peptides, 2002, May-15, Volume: 105, Issue:2

    Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Adrenal Glands; Angiotensins; Animals; Aorta; Female; Heart

2002
Type-1 and type-2 angiotensin II receptors in fetal rat brain.
    European journal of pharmacology, 1991, May-30, Volume: 198, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Autoradiography; Biphenyl Compounds; Brai

1991